Pharming: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Pharming (PHAR -3.64%) announced total revenue grew 21% to $117.6 million. Operating profit increased 89% to $29.9 million as the business expanded sales of its primary rare disease treatments. Strong cash generation gives the business funding to expand its clinical drug pipeline without needing extra financing.
Three things management said stand out.
1. Core Product RUCONEST Rebounds With Stable Patient Demand
RUCONEST, a treatment for hereditary angioedema (HAE, a rare genetic condition causing severe swelling), returned to revenue growth after earlier quarterly declines. Management maintained over 90% of active patients despite new oral competition, stabilizing demand among high-volume users.
RUCONEST revenue reached $93.8 million an increase of 14% year over year. Importantly, we have stabilized underlying US demand with volume returning to prior year levels.
— Leverne Marsh, Interim Co-Chief Executive Officer and Chief Commercial Officer
2. Joenja Accelerates Growth Through Geographic and Pediatric Expansion
Joenja, a therapy for activated phosphoinositide 3-kinase delta syndrome (APDS, a rare primary immunodeficiency causing immune system dysfunction), expanded through new international launches and U.S. Food and Drug Administration (FDA) pediatric approvals. International sales now generate roughly one-third of total Joenja revenue.
Joenja, a high growth asset still early in its life cycle, is expanding geographically and with a new pediatric indication. And a high value clinical pipeline with 2 potential billion dollar opportunities.
— Kenneth Lynard, Interim Co-Chief Executive Officer
3. Clinical Pipeline Targets Significantly Larger Immunodeficiency Markets
Management’s advancing leniolisib into common variable immune deficiency (CVID, a primary immunodeficiency disorder affecting immune function), a market 26 times larger than APDS in patient prevalence. Positive phase 2 data in related primary immunodeficiencies (PIDs) provides proof of concept for the broader indication.
The rationale for going beyond APDS is that there are other genetically defined PIDs and CVID patients with immune dysregulation who show similar PI3K delta driven biology. As a result, these populations share the same clinical manifestations we see in APDS.
— Anurag Relan, Chief Medical Officer
Looking Ahead
Operating profit is surging as commercial sales expand, and management isn’t hiding its satisfaction. High patient retention and specialized manufacturing create durable competitive moats. Management is strategically watching channel inventory timing and pediatric adoption.
We are running the company with discipline. Operating expenses were flat in the quarter, but operating profit rose 89%. And we ended the quarter with $191 million in cash.
— Kenneth Lynard, Interim Co-Chief Executive Officer
Disciplined execution and clinical expansion set up long-term growth across broader immunology markets.
Finally, our cash position of $190.9 million, together with future operating cash flows, is expected to cover our current pipeline and pre-launch costs.
— Kenneth Lynard, Interim Co-Chief Executive Officer
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.